Investment firms Baird and Wells Fargo have downgraded Inspire Medical Systems shares amid growing concerns about reimbursement challenges and weaker-than-expected performance. The cuts come as the medical device company faces uncertainty around insurance coverage for its sleep apnea treatment devices, potentially impacting revenue growth.

Inspire Medical's stock has been under pressure following reports of reduced reimbursement rates from major insurers. The company's implantable neurostimulation system, while innovative, relies heavily on favorable coverage decisions from Medicare and private insurers. Analysts cited both near-term headwinds and longer-term questions about the sustainability of current reimbursement levels.

The downgrades reflect broader concerns in the medical device sector about reimbursement headwinds. For Inspire, which went public in 2018, maintaining adequate insurance coverage is crucial for patient access and revenue growth. The company's shares have already declined significantly this year, making the analyst cuts particularly impactful for investors.